08 Feb 2025
Lifetime management - First valve choice matters
Sponsored by Edwards Lifesciences
Anchorperson:
R. Bhindi
Summary
In this expert-led session, explore new frontiers in TAVI, focusing on bicuspid aortic valves, small annulus, and the risk of secondary interventions. Gain insights from the latest randomized trials (RHEIA) and registry data (CAvEAT), with real-world case discussions highlighting their clinical impact.
Learning Objectives
- To discuss the new frontiers in TAVI including the treatment of patients with bicuspid aortic valve, small annulus and risk of secondary intervention
- To discover the results of latest randomised clinical trials (RHEIA) and registry data (CAvEAT) in these TAVI subsets
- To understand the clinical impact of these data sets through case presentations
/slide001.jpg)
/slide002.jpg)
/slide003.jpg)
/slide004.jpg)
/slide001.jpg)
/slide002.jpg)
/slide003.jpg)
/slide004.jpg)
/slide005.jpg)
/slide006.jpg)
/slide007.jpg)
/slide008.jpg)
/slide009.jpg)
/slide010.jpg)
/slide011.jpg)
/slide012.jpg)
/slide013.jpg)
/slide014.jpg)
/slide015.jpg)
/slide016.jpg)
/slide017.jpg)
/slide018.jpg)
/slide019.jpg)
/slide001.jpg)
/slide002.jpg)
/slide003.jpg)
/slide004.jpg)
/slide005.jpg)
/slide006.jpg)
/slide007.jpg)
/slide008.jpg)
/slide009.jpg)
/slide010.jpg)
/slide011.jpg)
/slide012.jpg)
/slide013.jpg)
/slide014.jpg)
/slide015.jpg)
/slide016.jpg)
/slide001.jpg)
/slide002.jpg)
/slide003.jpg)
/slide004.jpg)
/slide005.jpg)
/slide006.jpg)
/slide007.jpg)
/slide008.jpg)
/slide009.jpg)
/slide010.jpg)
/slide011.jpg)
/slide012.jpg)